[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recent-hiv-1-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recent-hiv-1-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100479779","phase-2-safety-tolerance-and-antiretroviral-activity-of-dasatinib-a-pilot-clinical-trial-in-patients-with-recent-hiv-1-infection-100479779",false,"NCT05527418","Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection","DASAHIVCURE","Inclusion Criteria:\n\n* 18 to 65 years.\n* Documented asymptomatic HIV-1 infection of 3-12 months duration (all patients must have a positive Western blot, including the p31 band whose appearance indicates infection of more than 90 days duration).\n* Not having received ART\n* CD4 T-lymphocyte count\\> 350 \u002F μl\n* Patient giving written informed consent\n\nExclusion Criteria:\n\n* Active HBV (HBsAg+ or DNA+) and\u002For HCV (RNA+) infection in screening.\n* ALT\\> 2 UNL, glomerular filtration rate \\\u003C70 mL \u002F 1.73 m2, leukocytes \\\u003C4000 \u002F mm3, total lymphocyte count \\\u003C1000 \u002F mm3, platelets \\\u003C100,000 \u002F mm3 or Hg \\\u003C12g \u002F dL.\n* Pregnancy or active breastfeeding\n* Ongoing or previous pleural effusion\n* Chronic obstructive pulmonary disease, bronchial asthma or recent chest trauma.\n* History of gastrointestinal or other bleeding.\n* Any concomitant treatment with potentially dangerous drug interaction with dasatinib.\n* Any clinical condition, at the opinion of the investigator, contraindicating participation (for example,\n* Active neoplastic disease, active concomitant infection, etc.)","ALL","18 Years","65 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Study to evaluate the safety, tolerability and antiretroviral activity of a new therapeutic strategy, based on the administration of dasatinib, an ITK, in patients with recent (3-12 months) asymptomatic HIV-1 infection.",[27],"Recent HIV-1 Infection","RECRUITING","2025-04-30",{"date":31,"type":32},"2025-05-01","ACTUAL",{"date":34,"type":32},"2024-01-26",{"date":36,"type":21},"2026-06",{"name":38,"class":39},"Eva Bonfill","OTHER"]